Women's health and kidney protective medications.
Curr Opin Nephrol Hypertens
; 33(5): 486-493, 2024 Sep 01.
Article
in En
| MEDLINE
| ID: mdl-38700904
ABSTRACT
PURPOSE OF REVIEW We discuss the sex-based differences in the pharmacokinetics and pharmacodynamics of kidney protective medications and their implications on women's health. RECENT FINDINGS:
A critical examination of adverse drug reactions highlights the underrepresentation of women in clinical trials for kidney and cardiovascular protective drugs, such as SGLT2 inhibitors, ACE inhibitors, and endothelin receptor antagonists. This underscores the need for sex-specific analyses in clinical studies to accurately assess medication efficacy and safety.SUMMARY:
The research demonstrates that women are more likely to experience adverse events and less likely to benefit from certain treatments, emphasizing the urgent need for healthcare providers to adopt a sex-informed approach in prescribing practices. Future research should prioritize sex differences from the outset to enhance understanding and improve clinical outcomes for women with chronic kidney disease and cardiovascular conditions.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Women's Health
/
Renal Insufficiency, Chronic
Limits:
Female
/
Humans
Language:
En
Journal:
Curr Opin Nephrol Hypertens
/
Curr. opin. nephrol. hypertens
/
Current opinion in nephrology and hypertension
Journal subject:
ANGIOLOGIA
/
NEFROLOGIA
Year:
2024
Document type:
Article
Affiliation country:
India
Country of publication:
Reino Unido